Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.

@article{Dumontet2009IxabepiloneTB,
  title={Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.},
  author={Charles Dumontet and Mary Ann Jordan and Francis Y. F. Lee},
  journal={Molecular cancer therapeutics},
  year={2009},
  volume={8 1},
  pages={17-25}
}
Microtubule-targeting agents, such as taxanes and epothilones, block mitosis and cell proliferation by targeting the dynamics of the cytoskeleton. The taxanes are widely used for treatment of various malignancies, but primary and acquired resistance to chemotherapy remains a significant clinical concern. Class I, II, III, IV, and V beta-tubulin isotypes are expressed in human tumors. Overexpression of the betaIII-tubulin isotype is one mechanism that can render tumor cells resistant to taxanes… CONTINUE READING
36 Citations
68 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 68 references

Ixabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III h-tubulin and breast cancer resistance protein

  • FYF Lee, M-L Wen, H Shen
  • Presented at the 6th European Breast Cancer…
  • 2008
Highly Influential
4 Excerpts

The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin has altered h-tubulin expression and is sensitive to ixabepilone

  • MA Jordan, H Miller, A Ray
  • Presented at the 97th AACR Annual Meeting, April
  • 2006
Highly Influential
4 Excerpts

expression by HIF - 1 a binding to its 3 ¶ flanking region

  • NM Mhaidat, RF Thorneb, CE deBock, XD Zhang, P Hersey
  • 2008

Similar Papers

Loading similar papers…